^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    1d
    GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas (clinicaltrials.gov)
    P1, N=18, Recruiting, Thomas Jefferson University | Not yet recruiting --> Recruiting | Trial completion date: Jan 2027 --> Apr 2028 | Trial primary completion date: Jan 2027 --> Oct 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    1d
    INTerpath-007: A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (clinicaltrials.gov)
    P2/3, N=46, Terminated, Merck Sharp & Dohme LLC | Completed --> Terminated; Business reasons
    Trial termination
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    1d
    Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects (clinicaltrials.gov)
    P1/2, N=70, Terminated, VBI Vaccines Inc. | Recruiting --> Terminated; VBI Bankruptcy
    Trial termination
    |
    EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • TERT (Telomerase Reverse Transcriptase) • CD4 (CD4 Molecule)
    |
    EGFR mutation • EGFR amplification • IDH wild-type
    |
    lomustine • carmustine • VBI-1901
    1d
    The Efficacy and Safety of Systemic Treatment for Managing Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-analysis. (PubMed, J Voice)
    Systemic bevacizumab remains the most mature systemic option with consistent real-world evidence and published dosing guidance. HPV-specific immunotherapy has recently transformed adult RRP management with an FDA-approved, short-course treatment option; ongoing studies will clarify optimal sequencing with bevacizumab and the role of checkpoint inhibition.
    Retrospective data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab)
    1d
    Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency. (clinicaltrials.gov)
    P=N/A, N=36, Active, not recruiting, University of Alberta | Trial completion date: Sep 2025 --> Jul 2026 | Trial primary completion date: Sep 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    1d
    A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=126, Recruiting, Johnson & Johnson Enterprise Innovation Inc. | N=96 --> 126
    Enrollment change
    |
    cetrelimab (JNJ-63723283)
    2d
    Advances in cell therapy for solid tumours: European perspective and future directions. (PubMed, Lancet Reg Health Eur)
    The recent US FDA approvals of lifileucel (a TIL therapy for advanced melanoma) and afamitresgene autoleucel (a TCR therapy targeting MAGE-A4 in synovial sarcoma) mark the first regulatory recognition of cell therapies for solid tumours and signal a new era for oncology...Emphasis is placed on emerging innovations like gene-edited and allogeneic therapies, as well as future directions for integrating cell therapies into mainstream oncology. We conclude with recommendations for overcoming barriers related to cost, toxicity management, and equitable access across Europe.
    Review • Journal
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    Tecelra (afamitresgene autoleucel) • Amtagvi (lifileucel)
    3d
    QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. (clinicaltrials.gov)
    P1, N=5, Completed, NantBioScience, Inc. | Active, not recruiting --> Completed | N=16 --> 5
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HR positive + HER-2 positive
    |
    YE-NEO 001
    3d
    A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants (clinicaltrials.gov)
    P3, N=2400, Not yet recruiting, Pfizer
    New P3 trial
    3d
    A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. (clinicaltrials.gov)
    P4, N=319, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | Trial completion date: Nov 2030 --> Apr 2029 | Trial primary completion date: Nov 2030 --> Apr 2029
    Enrollment closed • Trial completion date • Trial primary completion date
    3d
    A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine (clinicaltrials.gov)
    P3, N=1712, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    A Study of AT-02 in Subjects With Systemic Amyloidosis. (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Attralus, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> Sep 2026 | Trial primary completion date: Feb 2026 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date